The immunobiology of the receptor of advanced glycation end-products: Trends and challenges

Immunobiology

Volumn 218, Issue 5, 2013, Pages 790-797

  González, Ileana ^a   Romero, Jacqueline ^a   Rodríguez, Boris L ^b   Pérez Castro, Ramón ^a   Rojas, Armando ^a  

^a UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Alarmins; DAMPs; Inflammation; Innate immunity; PAMPs; RAGE; Toll receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID; AMYLOID BETA PROTEIN; CD11B ANTIGEN; COMPLEMENT COMPONENT C3A; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; OSTEONECTIN; PROTEIN S 100; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; BINDING AFFINITY; BINDING SITE; CPG ISLAND; HUMAN; IMMUNOBIOLOGY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TREND STUDY;

ADAPTIVE IMMUNITY; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIGANDS; ORGAN SPECIFICITY; POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84875660089     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.09.005     Document Type: Review

References (118)

1. Abdel-Azeez H.A., El-Okely A.M. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt. J. Immunol. 2009, 16:95-106.
2. Amir J., Waite M., Tobler J., Catalfamo D.L., Koutouzis T., Katz J., Wallet S.M. The role of hyperglycemia in mechanisms of exacerbated inflammatory responses within the oral cavity. Cell. Immunol. 2011, 272:45-52.
3. Andersoon U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 2011, 29:139-162.
4. Arce-Mendoza A., Rodriguez-de Ita J., Salinas-Carmona M.C., Rosas-Taraco A.G. Expression of CD64, CD206, and RAGE in adherent cells of diabetic patients infected with Mycobacterium tuberculosis. Arch. Med. Res. 2008, 39:306-311.
5. Balasubbu S., Sundaresan P., Rajendran A., Ramasamy K., Govindarajan G., Perumalsamy N., Hejtmancik J.F. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med. Genet. 2010, 11:158.
6. Barber G.N. Cytoplasmic DNA innate immune pathways. Immunol. Rev. 2011, 243:99-108.
7. Bazzoni F., Alejos E., Beutler B. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5376-5380.
8. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005, 83:876-886.
9. Boor P., Celec P., Klenovicsová K., Vlková B., Szemes T., Minárik G.J.T., Sebeková K. Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clin. Chim. Acta 2010, 411:1034-1140.
10. Carlo-Stella N., Bozzini S., De Silvestri A., Sbarsi I., Pizzochero C., Lorusso L., Martinetti M., Cuccia M. Molecular study of receptor for advanced glycation endproduct gene promoter and identification of specific HLA haplotypes possibly involved in chronic fatigue syndrome. Int. J. Immunopathol. Pharmacol. 2009, 22:745-754.
11. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K.T., Nawroth P.P. The pattern recognition receptor (RAGE) is a counter-receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 2003, 198:1507-1515.
12. Chen Y., Akirav E.M., Chen W., Henegariu O., Moser B., Desai D., Shen J.M., Webster J.C., Andrews R.C., Mjalli A.M., Rothlein R., Schmidt A.M., Clynes R., Herold K.C. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 2008, 181:4272-4278.
13. Chiodoni C., Colombo M.P., Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010, 29:295-307.
14. Curran C.S., Bertics P.J. Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand S100B. Int. Immunol. 2011, 223:713-728.
15. Daborg J., von Otter M., Sjolander A., Nilsson S., Minthon L., Gustafson D.R., Skoog I., Blennow K., Zetterberg H. Association of the RAGE G82S polymorphism with Alzheimer's disease. J. Neural. Transm. 2010, 117:861-867.
16. de Bouteiller O., Merck E., Hasan U.A., Hubac S., Benguigui B., Trinchieri G., Bates E.E., Caux C. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 2005, 280:38133-38145.
17. Demling N., Ehrhardt C., Kasper M., Laue M., Knels L., Rieber E.P. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 2006, 323:475-488.
18. dos Santos K.G., Canani L.H., Gross J.L., Tschiedel B., Pires Souto K.E., Roisenberg I. The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol. Genet. Metab. 2005, 85:149-156.
19. Dumitriu I.E., Baruah P., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 2005, 35:2184-2190.
20. Falcone C., Campo I., Emanuele E., Buzzi M.P., Geroldi D., Belvito C., Zorzetto M., Sbarsi I., Cuccia M. -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin. Chim. Acta 2005, 354:111-116.
21. Falcone C., Campo I., Emanuele E., Buzzi M.P., Zorzetto M., Sbarsi I., Cuccia M. Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int. J. Mol. Med. 2004, 14:1061-1064.
22. Falcone C., Emanuele E., Buzzi M.P., Ballerini L., Repetto A., Canosi U., Mazzucchelli I., Schirinzi S., Sbarsi I., Boiocchi C., Cuccia M. The -374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement. Int. J. Immunopathol. Pharmacol. 2007, 20:771-777.
23. Falcone C., Geroldi D., Buzzi M.P., Emanuele E., Yilmaz Y., Fontana J.M., Vignali L., Boiocchi C., Sbarsi I., Cuccia M. The -374T/A RAGE Polymorphism protects against future cardiac events in non-diabetic patients with coronary artery disease. Arch. Med. Res. 2007, 39:320-325.
24. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 2007, 81:28-37.
25. Friggeri A., Banerjee S., Biswas S., de Freitas A., Liu G., Bierhaus A., Abraham E. Participation of the receptor for advanced glycation end products in efferocytosis. J. Immunol. 2011, 186:6191-6198.
26. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem. Sci. 2011, 36:625-632.
27. Fritz G., Botelho H.M., Morozova-Roche L.A., Gomes C.M. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J. 2010, 277:4578-4590.
28. Frommhold D., Kamphues A., Hepper I., Pruenster M., Lukic I.K., Socher I., Zablotskaya V., Buschmann K., Lange-Sperandio B., Schymeinsky J., Ryschich E., Poeschl J., Kupatt C., Nawroth P.P., Moser M., Walzog B., Bierhaus A., Sperandio M. RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010, 116:841-849.
29. Fukata M., Abreu M.T. Pathogen recognition receptors, cancer and inflammation in the gut. Curr. Opin. Pharmacol. 2009, 9:680-687.
30. Gao J., Shao Y., Lai W., Ren H., Xu D. Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. J. Hum. Genet. 2010, 55:668-675.
31. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non- classical, vesicle-mediated secretory pathway. EMBO Rep. 2002, 3:995-1001.
32. Gu H., Yang L., Sun Q., Zhou B., Tang N., Cong R., Zeng Y., Wang B. Gly82Ser polymorphism of the receptor for advanced glycation end-products is associated with an increased risk of gastric cancer in a chinese population. Clin. Cancer Res. 2008, 14:3627-3632.
33. Haupt C., Morgado I., Kumar S.T., Parthier C., Bereza M., Hortschansky P., Stubbs M.T., Horn U., Fändrich M. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J. Mol. Biol. 2011, 405:341-348.
34. Heizmann C.W., Ackermann G.E., Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem. 2007, 45:93-138.
35. Hofmann M.A., Drury S., Hudson B.I., Gleason M.R., Qu W., Lu Y., Lalla E., Chitnis S., Monteiro J., Stickland M.H., Bucciarelli L.G., Moser B., Moxley G., Itescu S., Grant P.J., Gregersen P.K., Stern D.M., Schmidt A.M. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002, 3:123-135.
36. Hollá L., Kanková K.A.F., Bucková D., Halabala Znojil V., Vaněk J. Distribution of the receptor for advanced glycation end-products gene Pplymorphisms in patients with chronic periodontitis: a peliminary study. J. Periodontol. 2001, 72:1742-1746.
37. Hu X., Yagi Y., Tanji T., Zhou S., Ip Y.T. Multimerization and interaction of Toll and Spatzle in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9369-9374.
38. Huang J., Guh J., Chen H., Hung W.C., Lai Y.H., Chuang L.Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem. 2001, 81:102-113.
39. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., Grant P.J., Schmidt A.M. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22:1572-1580.
40. Hudson B.I., Stickland M.H., Futers T.S., Grant P.J. Effects f novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001, 50:1505-1511.
41. Hudson B.I., Stickland M.H., Grant P.J., Futers T.S. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 2001, 50:2646-2651.
42. Huttunen H., Kuja-Panula J., Rauvala H. RAGE signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J. Biol. Chem. 2002, 277:38635-38646.
43. Ito I., Fukazawa J., Yoshia M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 2007, 282:16336-16344.
44. Kalea A.Z., Schmidt A.M., Hudson B.I. Alternative splicing of RAGE: roles in biology and disease. Front. Biosci. 2011, 17:2756-2770.
45. Kalousova M., Jachymova M., Germanova A., Kubena A.A., Tesar V., Zima T. Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. Kidney Blood Press. Res. 2010, 33:30-36.
46. Kaňková K., Mrov I., Zhejsk J., Muk J., Stejskalov A., Znojil V., Vcha J. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism. 2001, 50:1152-1160.
47. Kaňková K., Stejskalová A., Pácal L., Tschoplová S., Hertlová M., Krusová D., Izakovičová-Hollá L., Beránek M., Vašků A., Barral S., Ott J. Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach. Diabetologia 2007, 50:990-999.
48. Kaňková K., Vasků A., Hájek D., Záhejský J., Vasků V. Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 1999, 22:1745.
49. Kaňková K., Záhejský J., Márová I., Muži{dotless}ók J., Kuhrová V., Blažková M., Znojil V., Beránek M., Vácha J. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J. Diabetes Complicat. 2001, 15:185-192.
50. Kazama H., Ricci J.E., Herdon J.M., Hoppe G., Green D.R., Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high- mobility group box-1 protein. Immunity 2008, 29:21-32.
51. Khandelwal P.J., Herman A.M., Moussa C.E. Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 2011, 238:1-11.
52. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., Schmidt A.M. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 1999, 274:31740-31749.
53. Kucukhuseyin O., Aydogan H.Y., Isbir C.S., Isbir T. Associations of -374T/A polymorphism of RAGE gene in Turkish diabetic and non-diabetic patients with coronary atery disease. In Vivo 2009, 23:949-954.
54. Li K., Dai D., Zhao B., Yao L., Yao S., Wang B., Yang Z. Association between the RAGE G82S polymorphism and Alzheimer's disease. J. Neural Transm. 2010, 117:97-104.
55. Lin L. RAGE on the Toll Road?. Cell. Mol. Immunol. 2006, 3:351-358.
56. Lindholm E., Bakhtadze E., Cilio C., Agardh E., Groop L., Agardh C.D. Association between LTA, TNF and AGER polymorphisms and late diabetic complications. PLoS One 2008, 3:e2546.
57. Lindholm E., Bakhtadze E., Sjögren M., Cilio C., Agardh E., Groop L., Agardh C.D. The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 2006, 49:2745-2755.
58. Liu G., Wang J., Park Y.J., Tsuruta Y., Lorne E.F., Zhao X., Abraham E. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 2008, 181:4240-4246.
59. Lu W., Feng B. The -374A allele of the RAGE gene as a potential protective factor for vascular complications in type 2 Diabetes: a meta-analysis. Tohoku J. Exp. Med. 2010, 220:291-297.
60. Manfredi A.A., Capobianco A., Esposito A., De Cobelli F., Canu T., Monno A., Raucci A., Sanvito F., Doglioni C., Nawroth P.P., Bierhaus A., Bianchi M.E., Rovere-Querini P., Del Maschio A. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 2008, 180:2270-2275.
61. Mantovani A., Marchesi F., Portal C., Allavena P., Sica A. Linking inflammation reactions to cancer: novel targets for therapeutic strategies. Adv. Exp. Med. Biol. 2008, 610:112-127.
62. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004, 322:1111-1122.
63. Moser B., Desai D.D., Downie M.P., Chen Y., Yan S.F., Herold K., Schmidt A.M., Clynes R. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 2007, 179:8051-8058.
64. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
65. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26:1129-1139.
66. Ostendorp T., Leclerc E., Galichet A., Koch M., Demling N., Weigle B., Heizmann C.W., Kroneck P.M., Fritz G. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007, 26:3868-3878.
67. Park I.H., Yeon S.I., Youn J.H., Choi J.E., Sasaki N., Choi I.H., Shin J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 2004, 40:1203-1211.
68. Parkin E., Harris B. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J. Neurochem. 2008, 108:1464-1479.
69. Pettersson-Fernholm K., Forsblom C., Hudson B.I., Perola M., Grant P.J., Groop P.H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in Type 1 diabetic patients. Diabetes 2003, 52:891-894.
70. Picheth G., Costantini C.O., Pedrosa F.O., Leme da Rocha Mar T., Maltempi de Souza E. The -374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients. Clin. Chem. Lab. Med. 2007, 45:1268-1272.
71. Pisetsky D.S., Erlandsson-Harris H., Andersson U. High- mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res. Ther. 2008, 10:209.
72. Poirier O., Nicaud V., Vionnet N., Raoux S.g.n., Tarnow L., Vlassara H., Parving H.-H., Cambien F. Polymorphism screening of four genes encoding advanced glycatione end-product putative receptors. Diabetes 2001, 50:1214.
73. Poon P.Y., Szeto C.C., Chow K.M., Kwan B.C., Li P.K. Relation between polymorphisms of receptor for advanced glycation end products (RAGE) and cardiovascular diseases in Chinese patients with diabetic nephropathy. Clin. Nephrol. 2010, 73:44-50.
74. Prevost G., Fajardy I., Besmond C., Balkau B., Tichet J., Fontaine P., Danze P.M., Marre M. Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab. 2005, 31:35-39.
75. Puntoni M., Marra D., Zanardi S., Decensi A. Inflammation and cancer prevention. Ann. Oncol. 2008, 19:225-229.
76. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer. 2009, 9:57-63.
77. Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium- binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway J. Biol. Chem. 1997, 272:9496-9502.
78. Ramsgaard L., Englert J.M., Manni M.L., Milutinovic P.S., Gefter J., Tobolewski J., Crum L., Coudriet G.M., Piganelli J., Zamora R., Vodovotz Y., Enghild J.J., Oury T.D. Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS One 2011, 6:e20132.
79. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22:3716-3720.
80. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
81. Rojas A., Figueroa H., Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010, 31:334-341.
82. Rojas A., González I., Rodríguez B., Romero J., Figueroa H., Llanos J., Morales E., Pérez-Castro R. Evidence of involvement of the receptor for advanced glycation end- products (RAGE) in the adhesion of Helicobacter pylori to gastric epithelial cells. Microbes Infect. 2011, 13:818-823.
83. Rojas A., Mercadal E., Figueroa H., Morales M.A. Advanced glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol. 2008, 6:44-51.
84. Rojas A., Morales M.A. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004, 76:715-730.
85. Rong L.L., Trojaborg W., Qu W., Kostov K., Yan S.D., Gooch C., Szabolcs M., Hays A.P., Schmidt A.M. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J. 2004, 18:1812-1817.
86. Rong L.L., Yan S.F., Wendt T., Hans D., Pachydaki S., Bucciarelli L.G., Adebayo A., Qu W., Lu Y., Kostov K., Lalla E., Yan S.D., Gooch C., Szabolcs M., Trojaborg W., Hays A.P., Schmidt A.M. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 2004, 18:1818-1825.
87. Ruan B.H., Li X., Winkler A.R., Cunningham K.M., Kuai J., Greco R.M., Nocka K.H., Fitz L.J., Wright J.F., Pittman D.D., Tan X.Y., Paulsen J.E., Lin L.L., Winkler D.G. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for advanced glycation end product- dependent manner. J. Immunol. 2010, 185:4213-4222.
88. Rudofsky G., Isermann B., Schilling T., Schiekofer S., Andrassy M., Schneider J.G., Morcos M., Humpert P.M., Sayed A.A., Witte S., Renn W., Pfohl M., Hamann A., Nosikov V., Schleicher E., Haring H.U., Ritz E., Nawroth P.P., Bierhaus A. A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2004, 112:135-141.
89. Sakaguchi M., Murata H., Yamamoto K., Ono T., Sakaguchi Y., Motoyama A., Hibino T., Kataoka K., Huh N.H. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011, 6:e23132.
90. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
91. Schenk S., Schraml P., Bendik I., Ludwig C.U. A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer 2001, 32:7-12.
92. Schlueter C., Hauke S., Flohr A.M., Rogalla P., Bullerdiek J. Tissue- specific expression patterns of the RAGE receptor and its soluble forms-a result of regulated alternative splicing?. Biochim. Biophys. Acta 2003, 1630(1):1-6. Oct 20;.
93. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 1999, 84:489-497.
94. Schmidt A.M., Stern M.D. Receptor for AGE (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci. 2001, 6:D1151.
95. Sorci G., Giovannini G., Riuzzi F., Bonifazi P., Zelante T., Zagarella S., Bistoni F., Donato R., Romani L. The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog. 2011, 7:e1001315.
96. Sorci G., Riuzzi F., Arcuri C., Giambanco I., Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol. Cell. Biol. 2004, 24:4880-4894.
97. Sturchler E., Galichet A., Weibel M., Leclerc E., Heizmann C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 2008, 28:5149-5158.
98. Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., Inoko H., Ikemura T. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994, 23:408-419.
99. Swann J.B., Vesely M.D., Silva A., Sharkey J., Akira S., Schreiber R.D., Smyth M.J. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:652-656.
100. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L.L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M.K., Fitzgerald K.A., Latz E., Kiener P.A., Coyle A.J. Toll-like receptor 9- dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8:487-496.
101. Tiszlavicz Z., Gyulai Z., Bencsik K., Szolnoki Z., Kocsis á., Somogyvári F., Vécsei L., Mándi Y. RAGE gene polymorphisms in patients with multiple sclerosis. J. Mol. Neurosci. 2009, 39:360-365.
102. van Beijnum J.R., Buurman W.A., Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99.
103. van Zoelen M.A.D., Achouiti M., van der Poll T. The role of the receptor for advanced glycation end-products (RAGE)in infection Crit. Care 2011, 15:1-8.
104. Vašků V.V., Kaňková K.K., Vašků A.V., Mužík J.M., Izakovičová Hollá L.I.H., Semrádová V.S., Vácha J.V. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch. Dermatol. Res. 2002, 294:127-130.
105. Verdier Y., Zarándi M., Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 2004, 10:229-248.
106. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann. N. Y. Acad. Sci. 2005, 1043:452-460.
107. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
108. Williams J.H., Ireland H.E. Sensing danger: Hsp72 and HMGB1 as candidate signals. J. Leukoc. Biol. 2008, 83:489-492.
109. Xie J., Burz D.S., He W., Bronstein I.B., Lednev I., Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem. 2007, 282:4218-4231.
110. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end-products (RAGE). J. Biol. Chem. 2008, 283:27255-27269.
111. Yamada Y., Fujii T., Ishijima R., Tachibana H., Yokoue N., Takasawa R., Tanuma S. The release of high mobility group box 1 in apoptosis is triggered by nucleosomal DNA fragmentation. Arch. Biochem. Biophys. 2011, 506:188-193.
112. Yamamoto Y., Harashima A., Saito H., Tsuneyama K., Munesue S., Motoyoshi S., Han D., Watanabe T., Asano M., Takasawa S., Okamoto H., Shimura S., Karasawa T., Yonekura H., Yamamoto H. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J. Immunol. 2011, 186:3248-3257.
113. Yan S.F., Ramasamy R., Schmidt A.M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Exp. Rev. Mol. Med. 2009, 11:e9.
114. Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 2010, 106:842-853.
115. Yeh C., Sturgis L., Haidacher J., Zhang X.N., Sherwood S.J., Bjercke R.J., Juhasz O., Crow M.T., Tilton R.G., Denner L. Requirement for p38 and p44/42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.
116. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., Yamamoto H. Novel splice variants of the receptor for advanced glycation end- products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 2003, 370:1097-1109.
117. Yoon S.-J., Park S., Shim C.Y., Park C.M., Ko Y.-G., Choi D., Park H.-Y., Oh B., Kim H., Jang Y., Chung N. Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coronary Artery Dis. 2007, 18:1-8.
118. Zhang L., Bukulin M., Kojro E., Roth A., Metz V.V., Fahrenholz F., Nawroth P.P., Bierhaus A., Postina R. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 2008, 283:35507-35516.